GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
PROTALIX BIOTHERAPEU (PLX) [hlAlert]

Rating:
Buy PLX
down 70.27 %

PROTALIX BIOTHERAPEU (PLX) rated Buy

Posted on: Tuesday,  Nov 20, 2007  9:25 AM ET by CIBC Wrld Mkts

CIBC Wrld Mkts rated Buy PROTALIX BIOTHERAPEU (AMEX: PLX) on 11/20/2007, when the stock price was $4.71. Since
then, PROTALIX BIOTHERAPEU has lost 70.28% as of 08/27/2015's recent price of $1.40.
If you would have followed this CIBC Wrld Mkts's recommendation on PLX, you would have lost 70.27% of your investment in 2837 days.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system. Using its ProCellEx system, the Company is developing a pipeline of recombinant therapeutic proteins based on its plant cell-based expression technology that target pharmaceutical markets and that rely upon known biological mechanisms of action. Its product development candidate, prGCD, is a plant cell expressed recombinant Glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. Its product pipeline includes, among other candidates, therapeutic protein candidates for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, an acetylcholinesterase enzyme-based therapy for biodefense and intoxication treatments and an additional undisclosed therapeutic protein.

CIBC World Markets strives to deliver leading edge investment research to investing clients through our multi-faceted, firm-wide research product offering. Our research has consistently been recognized as a top research source for its breadth of coverage, industry knowledge and quality of work in generating profitable and timely investment ideas. We provide in-depth coverage for all of the major sectors of the Canadian economy and select coverage of U.S. companies. Our analytical teams remain committed to identifying trends early and developing exploitable investment opportunities across the market capitalization spectrum. With the continued growth in quantitative and computerized investing strategies, we have also developed leading edge quantitative and technical research products to partner with our fundamental approach. Our products are available through several automated avenues: email, website, and third-party market vendors. Client service is our driving force and we constantly advance in offering greater product customization options.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/20/2007 9:25 AM Buy
None
4.71 7.00
as of 8/27/2015
1 Week down  -9.67 %
1 Month down  -32.03 %
3 Months down  -33.33 %
1 YTD down  -64.01 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy